logo
Eugenics ideas and a Natal Conference don't belong at the University of Texas

Eugenics ideas and a Natal Conference don't belong at the University of Texas

Yahoo26-03-2025

Years ago, I took a class at the University of Texas called anthropological genetics. Deborah Bolnick, an anthropologist and geneticist, taught us how humans have constructed and deconstructed our various groups. We learned that the racial categories of the United States Census have shifted several times. We learned that humans have more genetic diversity within a defined racial group than between them.
And very critically, we learned about eugenics, the notion that certain 'kinds' of people are better suited to reproduce. We learned how this was a guiding doctrine of Nazi science and the Jim Crow South, and was intertwined with similar dictums such as pronatalism — the idea that the 'right kind' of people should reproduce as much as possible. (You know which kind.)
The class gathered three times a week in a sunny room in Painter Hall, a 15-minute walk from the AT&T Hotel & Conference Center — another university-owned venue where later this week a conference on natalism and eugenics will be held. But bafflingly, this week's Natal Conference seeks not to decry eugenics, but to celebrate it.
At first glance this may not seem so bad. Survival of the fittest, after all? But the key question to ask here is this: Who gets to decide who the fittest are? And on which criteria? Are people of a certain race inherently better? Which combinations of nucleotides mark the best people?
Consider the speaking lineup for this conference. Instead of demographers — scientists who study populations and how they change — the lineup features far-right gadflies and prominent proponents of eugenicist ideas and practices, all with a stated aim to 'improve' future generations, not by investing in communities and the health and well-being of populations, but by developing policies of genetic selection that elevate and encourage the reproduction of white, abled people only.
But gadflies, by definition, exist to annoy. Arguing with them yields limited returns. And much to my dismay, UT has welcomed this event to our campus. While I urge university leadership in the strongest possible terms to disavow this embarrassing spectacle and protect our community from people who tweet cheerfully about the "butt rape" of Indigenous Americans, I doubt they will respond.
What we can do is this: Learn how horrific this movement is.
Read about the nonconsensual sterilization of prisoners in California, which wasn't stopped until 2013.
Read about the history of 'Mississippi Appendectomies,' the nonconsensual hysterectomies performed on Black women in teaching hospitals across the South.
Learn about Carrie Buck, the young woman who became pregnant by rape and was sterilized by a pro-eugenics physician who treated his patients as if they were cats who needed spaying.
Discuss these examples and their lessons with your friends and family. Do what you can with the emotional energy you have to counter this very ugly movement. Horrible things take root in ignorance.
While eugenics has never gone away, those who support it are more comfortable and publicly accepted than they have been in decades. It is especially concerning that they find comfort on the campus of our state's most celebrated public university, which has said it cannot discriminate against the viewpoints of anyone wishing to use the AT&T Conference Center.
The tacit approval of a race science conference at UT-Austin, alongside the large-scale defunding and muzzling of American science by a far-right regime, marks a very dark chapter of our history. It should worry all of us, not just academics, how quickly we've moved away from science, progress and the embrace of diversity.
We won't win every battle in this war. But no one can force us to forget our richly and beautifully diverse backgrounds as Americans, and our values as human beings. Consider this quote from the late Stephen Jay Gould, a paleontologist and one of the most celebrated and widely-read scholars in modern history:
'I am, somehow, less interested in the weight and convolutions of Einstein's brain than in the near certainty that people of equal talent have lived and died in cotton fields and sweatshops.'
Claire Zagorski is a graduate research assistant and PhD student in translational science at the University of Texas.
This article originally appeared on Austin American-Statesman: Natal Conference and eugenics don't belong at UT Austin | Opinion

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Yahoo

timea day ago

  • Yahoo

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds
Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds

Yahoo

time4 days ago

  • Yahoo

Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds

Historians have for a long time believed that leprosy was introduced to the Americas by European settlers, but the latest research offers strong evidence to the contrary – suggesting that Indigenous Americans had already been dying of the disease for centuries. The primary cause of leprosy is a bacterium called Mycobacterium leprae, and the researchers still think this was introduced to America by Europeans. However, it seems a lesser-known culprit was already established by that time. A new study from an international team of researchers found that another bacterium, Mycobacterium lepromatosis – a less common cause of leprosy infection – was present in the DNA of ancient human remains from Canada and Argentina dating back at least a thousand years. "This discovery transforms our understanding of the history of leprosy in America," says genomicist Maria Lopopolo, from the Institut Pasteur in France. "It shows that a form of the disease was already endemic among Indigenous populations well before the Europeans arrived." The M. lepromatosis bacteria was first discovered in a patient in the US in 2008, and since then it's also been found in red squirrels (Sciurus vulgaris) in the UK. It may well have spread from the US to the UK in the 19th century, the researchers suggest. In partnership with local Indigenous communities in terms of handling ancestral remains, the researchers analyzed the DNA from a total of 389 ancient and 408 modern human samples. From the results, they put together a genetic family tree of leprosy bacteria. Even though they were thousands of kilometers apart, the ancient Canadian and Argentinian samples were remarkably genetically similar. That points to a rapid spread of M. lepromatosis across the American continents. Based on the timeline put together from the DNA, the different strains of M. lepromatosis would have split from a common ancestor more than 9,000 years ago. With that many millennia of evolution under its belt, the team says there are likely even more diverse forms of the bacteria still waiting to be discovered in the Americas. "We are just beginning to uncover the diversity and global movements of this recently identified pathogen," says biologist Nicolás Rascovan, from the Institut Pasteur. "The study allows us to hypothesize that there might be unknown animal reservoirs." This all adds a valuable extra layer to our understanding of the history of the Americas, and of leprosy. It gives researchers some incredibly useful data points in terms of the progression and diversification of the disease. Infectious diseases play an important part in the story of North, South, and Central America, with the arrival of Europeans introducing a host of new pathogens that Indigenous communities weren't biologically prepared for. Now we know that the leprosy part of the picture is a lot more complicated than we previously realized. Around 200,000 new cases of the disease are reported worldwide every year, though it can now be treated and cured with modern drugs. "This study clearly illustrates how ancient and modern DNA can rewrite the history of a human pathogen and help us better understand the epidemiology of contemporary infectious diseases," says Rascovan. The research has been published in Science. Does Retinol Reverse Signs of Aging? Here's The Science. Meditation And Mindfulness Have a Dark Side We Often Overlook A Specific Kind of Birth Control May Increase Stroke Risk

Researchers develop face 'e-tattoo' to track mental workload in high-stress jobs
Researchers develop face 'e-tattoo' to track mental workload in high-stress jobs

Yahoo

time6 days ago

  • Yahoo

Researchers develop face 'e-tattoo' to track mental workload in high-stress jobs

Scientists say that they have formulated a way to help people in stressful and demanding work environments track their brainwaves and brain usage — an electronic tattoo device, or "e-tattoo," on the person's face. In a study posted in the science journal Device, the team of researchers wrote that they found e-tattoos to be a more cost-effective and simpler way to track one's mental workload. Dr. Nanshu Lu, the senior author of the research from the University of Texas at Austin, wrote that mental workload is a critical factor in human-in-the-loop systems, directly influencing cognitive performance and decision-making. Lu told Fox News Digital in an email that this device was motivated by high-demand, high-stake jobs such as pilots, air traffic controllers, doctors and emergency dispatchers. Teen Goes From 10 Nightly Seizures To Zero With Brain Implant Lu also said ER doctors and robot/drone operators can also leverage this technology for training and performance enhancements. Read On The Fox News App One of the goals of this study was to find a way to measure cognitive fatigue in high leverage and mentally straining careers. The e-tattoo is temporarily attached to the subject's forehead, and is smaller than current devices in use today. According to the study, the device works by using electroencephalogram (EEG) and electrooculogram (EOG) to measure both brain waves and eye movements. 8 Sleep Trackers To Help You Get A Better Night's Rest While most EEG and EOG machines are bulky and expensive, the e-tattoo offers a compact and cost-effective solution. Lu wrote that in this study, "we propose a wireless forehead EEG and EOG sensor designed to be as thin and conformable to the skin as a temporary tattoo sticker, which is referred to as a forehead e-tattoo." Lu also added that "human mental workload is a crucial factor in the fields of human-machine interaction and ergonomics due to its direct impact on human cognitive performance." The way the study was conducted was with six participants being shown a screen on which 20 letters flashed up, one at a time, at various locations. Participants were asked to click a mouse if either the letter itself, or its location, matched one shown a given number of letters. Each participant carried out the task multiple times, corresponding to four levels of difficulty. The team found that as the tasks became harder, the different types of brainwaves detected showed shifts in activity that corresponded to a higher mental workload response. The device consists of a battery pack and reusable chips with a disposable sensor. Lu said that the device is currently a lab prototype. "Before it can be ready for commercialization, it will need more development, such as real-time, on-tattoo mental workload decoding and validation on more people and in more realistic environments," she said. "The prototype currently costs $200."Original article source: Researchers develop face 'e-tattoo' to track mental workload in high-stress jobs

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store